Using caspofungin to treat Pneumocystis pneumonia in people with HIV.
Efficacy of Caspofungin for Pneumocystis Jirovecii Pneumonia in People Living With HIV/AIDS.
Instituto Nacional de Enfermedades Respiratorias · NCT06691321
This study is testing whether caspofungin can be a safer treatment for Pneumocystis pneumonia in people with HIV/AIDS compared to the usual medication.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Sponsor | Instituto Nacional de Enfermedades Respiratorias (other gov) |
| Locations | 1 site (Mexico City, Tlalpan) |
| Trial ID | NCT06691321 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the efficacy of caspofungin, an echinocandin, in treating Pneumocystis jirovecii pneumonia (PCP) in patients with HIV/AIDS. Given the safety concerns associated with the standard treatment, trimethoprim/sulfamethoxazole, this research aims to explore caspofungin's potential as a safer alternative. The study will include patients diagnosed with probable or proven PCP and will assess their clinical outcomes and safety profiles. The findings could provide valuable insights into the effectiveness of caspofungin in this vulnerable population.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with probable or proven Pneumocystis pneumonia and who are HIV-positive.
Not a fit: Patients who have switched to caspofungin after the first week of treatment or those with additional opportunistic lung infections may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could offer a safer treatment option for patients with Pneumocystis pneumonia, potentially reducing mortality and improving outcomes.
How similar studies have performed: While previous studies have shown promise for echinocandins in murine models, this approach in humans is still being explored and has limited documented data.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of probable or proven PCP, according to its diagnostic classification (refer to classification at the end of this section). * Have clinical laboratory and virological diagnostic laboratory studies at the time of admission. * Classification criteria for Pneumonia by P. jirovecii according to Robert-Gangneux et al.: Proven: Confirmation by pathology or microbiology. Possible: Presence of three out of four clinical or radiological criteria. Probable: Presence of one clinical or radiological criterion without another identified microorganism. Exclusion Criteria: * With a treatment switch to caspofungin after day 7 of treatment initiation (applies only to group B). * Patients who have developed an additional opportunistic lung infection during their hospitalization, other than cytomegalovirus pneumonitis or SARS-CoV-2 pneumonia.
Where this trial is running
Mexico City, Tlalpan
- Center for Research in Infectious Diseases (CIENI) — Mexico City, Tlalpan, Mexico (RECRUITING)
Study contacts
- Principal investigator: Santiago Avila, PhD — Center for Research in Infectious Diseases (CIENI)
- Study coordinator: Xavier Flores, MD
- Email: xavier.flores@cieni.org.mx
- Phone: (+52 55) 5940 2110
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: HIV-1-infection, Pneumocystis Pneumonia, Pneumocystis jirovecii pneumonia, Echinocandins, Caspofungin